Akatizie – častý, ale obtížně rozpoznatelný nežádoucí účinek?


Authors: Jindřiška Voláková
Published in the journal: Čas. Lék. čes. 2024; 162: 24-31
Category: Přehledové články

Summary

Drug induced akathisia is classified as an extrapyramidal adverse effect. Although akathisia is quite common extrapyramidal adverse effect, it is often overlooked or mistaken for restlessness or agitation of another etiology.

Drugs associated with the risk of extrapyramidal adverse effects (antipsychotics, antiemetics, antidepressants) belong to frequently used pharmacotherapy. The use of these drugs is often complicated by serious condition of a patient and several other comorbidities, which increase the risk of the aforementioned adverse effects. In many situations, akathisia can be more difficult to recognize and more easily attributed to non-drug etiology, especially outside the fields of psychiatry and neurology.

The variability of the clinical symptoms and the similarity to other clinical entities that occur frequently (anxiety, delirium, agitated depression, restless legs syndrome, etc.) can lead to difficult determination of the etiology and to the administration of medication, which tends to worsen the problem. At the same time, akathisia can be a source of very strong distress for a patient and fundamentally reduce his quality of life.

Keywords:

drug-induced movement disorders, akathisia, antipsychotics, antidepressants, antiemetics


Zdroje
  1. Chen JJ. Drug-induced movement disorders. Mental Health Clinician 2012; 1: 167–173.
  2. Burkhard PR. Acute and subacute drug-induced movement disorders. Parkinsonism Relat Disord 2014; 20 (Suppl 1): S108–S112.
  3. Baláž M, Kašpárek T. Extrapyramidové účinky léčiv – minimum pro farmaceuty. Prakt Lékáren 2017; 13: 151–155.
  4. Maršálek M. Tardivní dyskineze v praxi. Neurol Praxi 2001; 1: 39–41.
  5. Lohr JB, Eidt CA, Abdulrazzaq Alfaraj A Soliman MA. The clinical challenges of akathisia. CNS Spectr 2015; 20 (Suppl 1): 1–14.
  6. Mohr P, Volavka J. Ladislav Haskovec and akathisia: 100th anniversary. Br J Psychiatry 2002; 181: 537–537.
  7. Tachere RO, Modirrousta M. Beyond anxiety and agitation: A clinical approach to akathisia. Aust Fam Physician 2017; 46: 296–298.
  8. Factor AS. Acathisia. MedLink Neurology, 2023. Dostupné na: www.medlink.com/articles/antipsychotics
  9. Tašková I a kol. Psychofarmaka v kazuistikách: Modelové situace z preskripční praxe. Maxdorf, Praha, 2021.
  10. Zareifopoulos N, Katsaraki M, Stratos P et al. Pathophysiology and management of Akathisia 70 years after the introduction of the chlorpromazine, the first antipsychotic. Eur Rev Med Pharmacol Sci 2021; 25: 4746–4756.
  11. Loonen AJM, Stahl SM. The mechanism of drug-induced akathisia. CNS Spectr 2011; 16: 7–10.
  12. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672–676.
  13. Forcen FE. Akathisia: Is restlessness a primary condition or an adverse drug effect? Curr Psychiatry 2015; 14: 14–18.
  14. Hirose S. The causes of underdiagnosing akathisia. Schizophr Bull 2003; 29: 547–558.
  15. Salem H, Nagpal C, Pigott T, Teixeira AL. Revisiting antipsychotic-induced akathisia: current issues and prospective challenges. Curr Neuropharmacol 2017; 15: 789–798.
  16. Huhn M, Nikolakopoulou A, Schneider-Thoma J et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 2019; 394: 939–995.
  17. Taylor D et al. The Maudsley Prescribing Guidelines in Psychiatry (13th ed.). Wiley Blackwell, London, 2018.
  18. Factor S, Lang A, Weiner W. Drug Induced Movement Disorders (2nd ed.). Wiley Blackwell, London, 2008.
  19. Martino D, Karnik V, Osland S et al. Movement disorders associated with antipsychotic medication in people with schizophrenia: an overview of Cochrane Reviews and Meta-Analysis. Can J Psychiatry 2018; 63: 706743718777392.
  20. Revet A, Montastruc F, Roussin A et al. Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database. BMC Psychiatry 2020; 20: 308.
  21. Raveendranathan D, Swaminath GR. Mirtazapine induced akathisia: understanding a complex mechanism. Indian J Psychol Med 2015; 37: 474–475.
  22. European Medicines Agency recommends changes to the use of metoclopramide. EMA, 2013. Dostupné na: www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-changes-use-metoclopramide_en.pdf
  23. FDA requires boxed warning and risk mitigation strategy for metoclopramide-containing drugs. FDA, 2009. Dostupné na: www.fiercebiotech.com/biotech/fda-requires-boxed-warning-and-risk-mitigation-strategy-for-metoclopramide-containing-drugs
  24. Dy AMB, Limjoco LLG, Jamora RDG. Trimetazidine-induced parkinsonism: a systematic review. Front Neurol 2020; 11: 44.
  25. Berna F, Misdrahi D, Boyer L et al. Akathisia: prevalence and risk factors in a community-dwelling sample of patients with schizophrenia. Results from the FACE-SZ dataset. Schizophr Res 2015; 169: 255–261.
  26. Tinajero JC, Fabbri A, Dufau ML. Serotonergic inhibition of rat Leydig cell function by propranolol. Endocrinology 1993; 133: 257–264.
  27. Lima AR, Bacalcthuk J, Barnes TR Soares-Weiser K. Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev 2004; 4: CD001946.
  28. Pringsheim T, Gardner D, Addington D et al. The assessment and treatment of antipsychotic-induced akathisia. Can J Psychiatry 2018; 63: 719–729.
  29. Dupuis B, Catteau J, Dumon JP et al. Comparison of propranolol, sotalol, and betaxolol in the treatment of neuroleptic-induced akathisia. Am J Psychiatry 1987; 144: 802–805.
  30. Kim A, Adler L, Angrist B Rotrosen J. Efficacy of low-dose metoprolol in neuroleptic-induced akathisia. J Clin Psychopharmacol 1989; 9: 294–296.
  31. Reiter S, Adler L, Angrist B et al. Atenolol and propranolol in neuroleptic-induced akathisia. J Clin Psychopharmacol 1987; 7 (4): 279–280.
  32. Zubenko GS, Cohen BM, Lipinski JF Jr, Jonas JM. Use of clonidine in treating neuroleptic-induced akathisia. Psychiatry Res 1984; 13: 253–259.
  33. Lima AR, Soares-Weiser K, Bacaltchuk J, Barnes TR. Benzodiazepines for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev 2002; 1: CD001950.
  34. Friis T, Christensen TR, Gerlach J. Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism and hyperkinesia. A double-blind cross-over study with placebo. Acta Psychiatr Scand 1983; 67: 178–187.
  35. Caroff SN, Jain R, Morley JF. Revisiting amantadine as a treatment for drug-induced movement disorders. Ann Clin Psychiatry 2020; 32: 198–208.
  36. Poyurovsky M, Weizman A. Treatment of antipsychotic-induced akathisia: role of serotonin 5-HT2a receptor antagonists. Drugs 2020; 80: 871–882.
  37. Praharaj SK, Kongasseri S, Behere RV, Sharma PS. Mirtazapine for antipsychotic-induced acute akathisia: a systematic review and meta-analysis of randomized placebo-controlled trials. Ther Adv Psychopharmacol 2015; 5: 307–313.
  38. Jethwa K. Pharmacological management of antipsychotic-induced akathisia: an update and treatment algorithm. B J Psych Advances 2015; 21: 342–344.
  39. Ustohal L, Baláž M. Léčba EPS – akutní a tardivní dystonie a dyskineze. Doporučené postupy psychiatrické péče. Psychiatrická společnost ČLS JEP, 2018. Dostupné na: https://postupy-pece.psychiatrie.cz/lecba/dystonie-dyskineze/lecba-eps  
  40. Bhidayasiri R, Jitkritsadakul O, Friedman JH et al. Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. J Neurol Sci 2018; 389: 67–75.
  41. Blanchet PJ. A focused update on tardive dyskinesia. Can J Neurol Sci 2020; 47: 747–755.
Štítky
Adiktológia Alergológia a imunológia Angiológia Audiológia a foniatria Biochémia Dermatológia Detská gastroenterológia Detská chirurgia Detská kardiológia Detská neurológia Detská otorinolaryngológia Detská psychiatria Detská reumatológia Diabetológia Farmácia Chirurgia cievna Algeziológia Dentální hygienistka

Článok vyšiel v časopise

Časopis lékařů českých

Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Kurzy

Zvýšte si kvalifikáciu online z pohodlia domova

Eozinofilní granulomatóza s polyangiitidou
nový kurz
Autori: doc. MUDr. Martina Doubková, Ph.D.

Všetky kurzy
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa